Allergan provided the following FAQ related to the recent Federal District Court patent decision on Restasis®:

1) **Please help us understand the District Court's decision issued on 10/16/17:**
   - A Federal Judge sitting in the United States District Court for the Eastern District of Texas issued his decision on the patent challenge of Restasis® in favor of the defendants, finding the patents are invalid. We are obviously disappointed with the Court's invalidity decision, and plan to appeal that ruling.
   - The Judge found that the ANDA products do infringe the Allergan patents, but invalidated the patents on obviousness grounds.

2) **What are the next steps in terms of timing?**
   - Typically, the appeals process takes approximately 12 months, and we are considering seeking an injunction pending appeal, if necessary.
   - However, the appeals process may be accelerated and an injunction may not be granted.
   - A late 2018/early 2019 generic launch is reasonable under the following assumptions: i) there is an FDA approved generic product by that time; ii) the appeal process takes approximately 12 months, which is a typical time horizon, and iii) a court grants an injunction pending appeal.
   - It is possible that a generic entrant may enter earlier if: i) there is an FDA approval for a generic product, ii) such approved generic product is launched "at-risk" and/or iii) there is an earlier adverse final court decision.

3) **In the face of this uncertainty, how is Allergan planning to manage for 2018?**
   - We will continue to support Restasis® with an appropriate level of promotional investment and we remain committed to eye care professionals and patients.
   - Given the uncertainty about timing, we will take a conservative approach as we plan 2018.
   - While opinions on the subject may vary, anticipating a generic launch in early 2018, while conservative, could be an appropriate assumption.
   - We will provide you with a general framework on the potential annual impact from generic competition on Restasis® in our Q3 earnings call.

4) **Are there any approved generics, and is there a "first applicant"?**
   - We currently are not aware of any FDA-approved generic products.
   - Allergan does not believe that the Food & Drug Administration has issued a sufficient regulatory guidance to provide a clear pathway to approval for a proposed generic version of this product.
   - Further, as far as we know, FDA has not made a determination as to whether any of the generics is a "first applicant" entitled to exclusivity.

5) **How does this decision impact the IPR process?**
   a. The IPR process, which will continue to play out, is distinct from the district court litigation. That is the essence of the "double jeopardy" we have been discussing.